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ADAMTS-4_v1 Is a Splice Variant of ADAMTS-4
That Is Expressed as a Protein in Human Synovium
and Cleaves Aggrecan at the Interglobular Domain
Shane D. Wainwright, Jan Bondeson, Bruce Caterson, and Clare E. Hughes
Objective. We previously described a messenger
RNA variant of ADAMTS4 (ADAMTS4_v1) in human
synovial cell cocultures obtained from patients with
osteoarthritis (OA). This RNA message has been
found only in OA synovium and, if translated, would
result in a protein identical to ADAMTS-4, except that
the C-terminal spacer domain would be different. The
purpose of this study was to determine whether
ADAMTS4_v1 is translated into a protein, is expressed
in vivo, and acts as a functional aggrecanase.
Methods. Polyclonal antibodies were raised
against unique C-terminal sequences of ADAMTS-4_v1.
An immunohistochemical study of human OA syno-
vium was performed. A mammalian expression vector
coding for FLAG-tagged human ADAMTS4 was mutated
to contain the different sequences of ADAMTS4_v1, and
the resultant plasmid was used to transfect HEK 293
cells. ADAMTS-4_v1 produced by these cells was puri-
fied via the FLAG epitope, and the ability of this
recombinant protein to cleave aggrecan, biglycan, and
decorin was investigated.
Results. An antibody specific for ADAMTS-4_v1
was found to bind to the synovial membrane surface on
cryosections, and the protein was detected in cell lysates
from synovium obtained from OA patients. The recom-
binant ADAMTS-4_v1 demonstrated enzyme activity
toward the target substrate in a commercial aggreca-
nase 1 enzyme-linked immunosorbent assay and was
also found to cleave aggrecan at the pathologically
important Glu3732374Ala aggrecanase site.
Conclusion. ADAMTS-4_v1 is expressed as a pro-
tein in vivo in human OA synovium, functions as an
aggrecanase, and cleaves other proteoglycan substrates.
This splice variant may be a major contributor to loss of
aggrecan from the superficial zone of OA cartilage.
Osteoarthritis (OA) is a multifaceted disease that
involves pathologic changes in the articular cartilage,
subchondral bone, surrounding soft tissue, and synovium
(1,2). Inflammation and proliferation of the synovium
are reported in both the early and late stages of OA
(3,4). Synovial tissue characteristically becomes thick-
ened, and higher synovial fluid volumes are correlated
with progression of OA, joint space narrowing, and bone
marrow lesions (1). Inflamed OA synovial tissue is
known to release a plethora of cytokines and proteinases
capable of degrading nearby cartilage and other connec-
tive tissues.
OA synovium produces several members of the
ADAMTS family of metalloproteinases, including
ADAMTS-4 and ADAMTS-5, key enzymes involved in
the cleavage of aggrecan and the degradation of carti-
lage (5–7). Aggrecan degradation and loss from cartilage
is an early and crucial event in the development of OA,
contributing to the loss of function and the development
of joint pain that are manifested in this disease. Contri-
butions made by ADAMTS-4 and ADAMTS-5 in the
progression of human OA are ambiguous, with studies
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showing involvement of one or both of these enzymes
(8–11). We have previously reported that culture of a
mixed population (coculture) of human synovial cells
derived from OA synovium express messenger RNA
(mRNA) that encodes for a splice variant of ADAMTS-4,
with the potential of producing a protein with a
C-terminal spacer domain sharing no homologies with
the ADAMTS-4 spacer domain (12). This mRNA has so
far been found only in OA synovium and has not been
detected in any other joint tissue, including OA carti-
lage. The resultant splice-variant protein is predicted to
retain enzyme specificity for aggrecan degradation, al-
though properties dependent on the ADAMTS-4 spacer
domain would be lost.
In the present study, we describe the produc-
tion and characterization of this splice variant, named
ADAMTS-4_v1, as a recombinant protein. We pro-
duced antibodies to its C-terminal domain and showed
that it is expressed as a protein in synovial tissue from
OA patients, and we investigated its ability to cleave
aggrecan in the interglobular domain (IGD) and de-
grade other matrix proteoglycans.
MATERIALS AND METHODS
Construction of ADAMTS4_v1-pCEP4 plasmid.
ADAMTS4.1-pCEP4 containing the complementary DNA of
human ADAMTS4 3 FLAG in the pCEP4 plasmid (Invitro-
gen) was a gift from Hideaki Nagase (Imperial College Lon-
don, London, UK). The 162 basepairs from the 5 end of exon
9 were removed using a QuikChange XL site-directed mu-
tagenesis kit (Agilent Technologies), with primers named
CEH310 (5-GTCAGGCTCCTTCAGGAAATTCAGATGT-
GGTACTGCCTGGGGCAGTCAGC-3) and CEH311 (5-
GCTGACTGCCCCAGGCAGTACCACATCTGAATTTCC-
TGAAGGAGCCTGAC-3). The product CEH310/311-pCEP4
lacked the sequence between the stop codons of ADAMTS4
and ADAMTS4_v1. The missing sequence was inserted using
the unique Bst ZI restriction enzyme site in exon 9 of
ADAMTS4. CEH310/311 was cut out and ligated into pBlue-
script (Agilent Technologies), and the sequence lying 3 of the
Bst ZI site was removed. The 3 end of ADAMTS4_v1 was
constructed by reverse transcription–polymerase chain reac-
tion (RT-PCR) of RNA extracted from OA synovial cells, as
described previously (12), using an Advantage 2 PCR kit (BD
Biosciences) with primers named CEH319 (5-CACACGCC-
TCCGATACAGCTTCTTC-3) and CEH320 (5-GGCAGT-
TTAGATGGAGGGCTGTCTG-3). The FLAG sequence
was added using sequential PCR with the primers named
CEH319 and CEH321 (5-ATCGTCATCTTTATAATCCTG-
CCTCCCAGGGCAGGAAACCAG-3), followed by primers
CEH319 and CEH322 (5-GAGCTCGAGTTACTTGTCAT-
CGTCATCTTTATAATCCTGCCT-3). The product
CEH319/322 was ligated into Bst ZI/Sac I–cut CEH310/311-
pBluescript. The complete sequence of ADAMTS4_v1 was cut
from pBluescript using Kpn I and Xho I and then ligated into
pCEP4. The ADAMTS4_v1-pCEP4 was subjected to DNA
sequencing using in-house facilities.
Production of recombinant proteins. ADAMTS4.1-
pCEP4 and ADAMTS4_v1-pCEP4 were stably transfected into
HEK 293 cells maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 250 g/ml of G418, 1
antibiotic/antimycotic solution, and 10% fetal bovine serum
(FBS; Invitrogen) using FuGene 6 (Roche Diagnostics) ac-
cording to the manufacturer’s protocol. After 48 hours, the
cells were transferred to medium supplemented with 200 g/ml
of hygromycin B (Invitrogen) for selection. Cells were main-
tained in this medium and were harvested and the medium was
replenished every 3 days.
Purification of FLAG-labeled recombinant proteins by
immunoprecipitation. Cells were harvested by centrifugation
at 400g, washed in phosphate buffered saline (Dulbecco A
solution; Oxoid), and incubated for 30 minutes at 4°C in lysis
buffer (1% Triton X-100, 50 mM Tris HCl, pH 7.4, 1 mM
EDTA, 150 mM NaCl, and Halt protease inhibitor cocktail
[Thermo Scientific]). The lysate was cleared by centrifugation
at 12,000g for 10 minutes at 4°C. Conditioned medium was
precleared by centrifugation at 400g and filtered using a
0.22-m Stericup/Steritop filter unit (Millipore). The cell
lysate or conditioned medium was incubated for 4 hours at 4°C
with 40 l of anti–FLAG M2 affinity gel (Sigma). The gel was
washed in lysis buffer and Tris buffered saline (TBS; 50 mM
Tris HCl, pH 7.4, 150 mM NaCl), and bound proteins were
eluted by incubation with 150 ng/l of 3 FLAG peptide
(Sigma) in TBS for 30 minutes at 4°C. Eluted proteins were
recovered by centrifugation, filtered (0.22-m Ultrafree-MC
filter units [Millipore]), and stored at 80°C.
Production of antibodies to the C-terminus of
ADAMTS-4_v1. Sequences 735PGHTPPIQLLRAPADP750
(AltTS4.1) and 805RELLLLPHAKTQWGGAVGVRP825
(AltTS4.2) of ADAMTS-4_v1 were selected using the EMBOSS
software program (13) and synthesized on multiantigenic
peptide cores and controlled-pore glass (Alta Bioscience).
Rabbits were immunized subcutaneously (500 g per injec-
tion) with either the AltTS4.1 or the AltTS4.2 ADAMTS-4_v1
sequences in Freund’s complete adjuvant and were given 4
booster injections in Freund’s incomplete adjuvant at 28-day
intervals. Animals were bled 14 days after each booster immu-
nization. Antibodies were affinity-purified on peptide-coated
controlled-pore glass according to the manufacturer’s protocol.
Sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blotting. Samples were
subjected to SDS-PAGE using either 10% or 4–12% gels
(Invitrogen) and transferred to Protran nitrocellulose mem-
branes (Whatman) using a Bio-Rad Mini Trans-Blot cell.
Samples were then blocked with 5% (weight/volume) bovine
serum albumin (BSA) in TSA (50 mM Tris HCl, pH 7.4,
200 mM NaCl, 0.02% [w/v] sodium azide) and probed with
antibody in 1% (w/v) BSA in TSA, followed by alkaline
phosphatase–conjugated anti-mouse IgG (Promega) or anti-
rabbit IgG (Dako). Color was developed with BCIP/nitroblue
tetrazolium substrate (Promega). Protein bands were visual-
ized with Coomassie brilliant blue R250. Primary antibodies
ab28285 and ab39201 were from Abcam and BAF4307 from
R&D Systems.
Immunohistochemistry. Synovium was obtained from
2 patients undergoing knee replacement surgery for OA
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(ethical consent was obtained according to South East Wales
Local Research Ethics Committees directive DEBP/el/03-
5102). Samples were embedded in OCT (Fisher Scientific)
using liquid nitrogen-cooled isopentane, and 10-m tissue
sections were cut, air-dried, and fixed with ice-cold 90%
ethanol. The sections were washed in 0.1% Tween 20 in PBS,
blocked for 20 minutes with 2.5% horse serum in PBS, and
incubated for 20 minutes in 2.5% horse serum with the primary
antibody. Binding was detected with a Ready-to-Use Vec-
tastain kit (Vector), visualized with the use of a Vector
NovaRED kit, counterstained with Mayer’s hemalum, dehy-
drated, and mounted in DPX mountant.
Isolation and culture of synovial cells. Synovium from
2 patients with OA was trimmed of fat, diced, and digested for
2 hours at 37°C with 1 mg/ml of collagenase I and DNase in
DMEM containing 10% FBS (14). The suspension was filtered
through a 40-m cell strainer. Cells were plated at 2  106 /ml
and cultured for 48 hours prior to solubilization in lysis buffer
for SDS-PAGE and Western blotting.
Aggrecanase 1/ADAMTS-4 assay. A SensoLyte 520
aggrecanase 1 assay kit (AnaSpec) was used to detect aggre-
canase 1/ADAMTS-4 activity. Truncated human ADAMTS-4
(0.251 pmoles) in 50 l of component C, 50 l of purified
ADAMTS-4_v1, or 50 l of furin-activated ADAMTS-4_v1
was added to the wells of a black Sera-Wel 96-well microtiter
plate (Sterilin). Diluted aggrecanase substrate buffer (50 l)
was added, and the plate was incubated at 37°C for 1 hour in
a FluoStar Optima microplate instrument (BMG Lab Tech-
nologies), with monitoring at 490 nm/520 nm excitation/
emission spectra and readings obtained every 5 minutes.
Aggrecanase assay. Bovine aggrecan (20 g; Sigma)
was incubated overnight at 37°C in the presence or absence
of 2 units of furin (New England Biolabs), with purified
ADAMTS-4, ADAMTS-4_v1, or anti-FLAG immunoprecipi-
tates from cell lysates of untransfected HEK 293 cells, in TBS
containing 10 mM CaCl2. Digests were deglycosylated with
chondroitinase ABC (Sigma), keratanase, and keratanase II
(Seikagaku Kogyo) and then subjected to Western blotting
with the aggrecan IGD aggrecanase site-specific neoepitope
monoclonal antibody (mAb) BC-3 (15).
Digestion of small leucine-rich proteoglycans by
ADAMTS-4 and ADAMTS-4_v1. Bovine nasal cartilage was
extracted and subjected to associative density-gradient ultra-
centrifugation as previously described (16). The A3 extract
(25 g per digestion) was incubated overnight at 37°C with
either purified ADAMTS-4 or ADAMTS-4_v1 or with anti-
FLAG immunoprecipitates from cell lysates of untransfected
HEK 293 cells, in TBS containing 10 mM CaCl2. Digests were
deglycosylated (15) and subjected to Western blotting using
either the biglycan-specific mAb PR-1 (17) or the decorin-
specific mAb 70.6 (18).
RESULTS
Production and characterization of ADAMTS-
4_v1. The splice variant plasmid was used to stably
transfect HEK 293 cells. A Coomassie brilliant blue
R250–stained SDS-PAGE gel of anti-FLAG immuno-
precipitates from detergent lysates of ADAMTS4_v1-
Figure 1. Characterization of recombinant ADAMTS-4_v1. A, Blot of
anti–FLAG M2 monoclonal antibody (mAb) immunoprecipitates from
Triton X-100 extracts of untransfected HEK 293 cells and ADAMTS4_v1-
pCEP4–transfected HEK 293 cells, following sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and Coomassie brilliant blue R250
staining. The band marked with an asterisk yielded an N-terminal amino
acid sequence of ASPLPRE…, whereas no sequence was obtained from
the band marked with a double asterisk. B–D, Triplicate Western blots of
anti–FLAG M2 mAb immunoprecipitates from Triton X-100 cell extracts
and conditioned media obtained from untransfected, ADAMTS4.1-
pCEP4–transfected, or ADAMTS4_v1-pCEP4–transfected HEK 293
cells, probed with anti–FLAG M2 mAb (B), a rabbit antiserum (ab28285)
to the carboxyl-terminus of ADAMTS-4 (C), or a rabbit antiserum
(ab39201) to the pro domain of ADAMTS-4 (D). E, Western blot of
anti–FLAG M2 mAb immunoprecipitates from a Triton X-100 extract of
an equal number of Tris buffered saline–washed ADAMTS4_v1-pCEP4–
transfected HEK 293 cells (Triton X-100 extract), a Triton X-100 extract
of the pellet after high salt extraction (high salt pellet), and a 1M NaCl,
50 mM Tris HCl, pH 7.4, extract of ADAMTS4_v1-pCEP4–transfected
HEK 293 cells (high salt extract). F, Western blot probed with anti–
FLAG M2 mAb using a plasma membrane protein extraction kit to
prepare cytosol, total membranes, and plasma membranes from
ADAMTS4_v1-pCEP4–transfected HEK 293 cells prior to anti–FLAG
M2 mAb immunoprecipitation.
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pCEP4–transfected HEK 293 cells showed 2 prominent
bands at 104 and 82 kd (Figure 1A) that were absent
in immunoprecipitates from untransfected cells. Pro-
tein sequence analysis of the 104-kd band (Figure 1A)
revealed ASPLPRE…, corresponding to the predicted
N-terminus for the recombinant band, while no se-
quence was obtained from the 82-kd band (Figure 1A).
These bands match closely with the predicted molecular
weight of 91 kd and 69 kd for the full-length and
furin-activated ADAMTS-4_v1 proteins.
To further characterize these proteins, we
performed a series of Western blots on purified
ADAMTS-4_v1 and ADAMTS-4 from either cell ex-
tracts or conditioned medium. A Western blot of puri-
fied ADAMTS-4_v1 from cell extracts and media (Fig-
ure 1B) that was probed with the anti–FLAG M2 mAb,
showed a prominent band of 104 kd and a weaker
band of 82 kd, confirming that these bands represented
2 different forms of ADAMTS-4_v1. Further FLAG-
containing bands of 88, 67, and 48 kd were seen in the
immunoprecipitate from the cell extracts (Figure 1B)
and may represent lower molecular weight break-
down products of ADAMTS-4_v1. The apparent 104
and 82 kd for ADAMTS-4_v1 were slightly slower
migrating than bands detected in purified ADAMTS-4
from cell extracts and media (Figure 1B).
The 104- and 82-kd bands of ADAMTS-4_v1 did
not label with an antibody to the carboxyl-terminus
of ADAMTS-4 (Figure 1C); however, as expected,
this antibody did label ADAMTS-4 proteins of 95 kd
and 70 kd (Figure 1C). In contrast, an antibody react-
ing with the pro domain of ADAMTS-4 labeled
only the 104-kd ADAMTS-4_v1 protein and the 95-kd
ADAMTS-4 protein (Figure 1D). Interestingly, this
antibody also detected a 104-kd band in ADAMTS-4_v1
purified from the conditioned media (Figure 1D). A
70-kd cross-reactive band (as reported by Abcam) was
detected in all cell extracts (Figure 1D). Taken together,
these data show that ADAMTS4_v1-pCEP4–transfected
HEK 293 cells produced the full-length ADAMTS-4_v1
protein and an 82-kd form minus its pro domain; both
forms were found in the conditioned media.
To determine whether ADAMTS-4_v1 is se-
creted as a peripheral membrane protein, a high salt
extract of ADAMTS-4_v1-transfected HEK 293 cells
was prepared and analyzed by Western blotting (Figure
1E). Interestingly, the proenzyme was extracted from
the cells using high salt. Further analysis of cytosol,
total membranes, and plasma membranes from these
cells showed the presence of proenzyme in all of these
cellular extracts (Figure 1F).
Production and characterization of antibodies to
the C-terminal domain of ADAMTS-4_v1. Polyclonal
antibodies specific to ADAMTS-4_v1, named AltTS4.1
and AltTS4.2, were used to probe Western blots of
both synthetic peptides. It was found that the antibodies
labeled only their corresponding peptide, with no evi-
dence of cross-reactivity (data not shown). Western blots
were performed on detergent lysates from untransfected
HEK 293 cells or from HEK 293 cells producing either
ADAMTS-4_v1 or ADAMTS-4. Both antibodies labeled
a 104-kd band in the ADAMTS-4_v1 lysate (Figures 2A
and B), with no reactivity with the ADAMTS-4 lysate
(Figures 2A and B) or with the lysate from untransfected
cells (Figures 2A and B).
AltTS4.1 appeared to have a lower affinity for
the 104-kd band and have some cross-reactivity with
higher molecular weight bands in all the lysates (Fig-
Figure 2. Characterization of antisera raised against the ADAMTS-4_v1 synthetic peptides. A and B, Western blots of Triton X-100 extracts of HEK
293 cells transfected with ADAMTS4_v1-pCEP4 (lane 1), ADAMTS4.1-pCEP4 (lane 2), or left untransfected (lane 3) and probed with the AltTS4.1
serum (A) or the AltTS4.2 serum (B). C, Western blot of a Triton X-100 extract of HEK 293 cells transfected with ADAMTS4_v1-pCEP4 and probed
with affinity-purified AltTS4.2 antibodies (lane 1) or with affinity-purified AltTS4.2 antibodies that had been preincubated with 5 g/ml of the
AltTS4.2 peptide (lane 2). D and E, Duplicate Western blots of anti-FLAG immunoprecipitates from Triton X-100 cell extracts (lanes 1, 3, and 5)
and conditioned media (lanes 2, 4, and 6) from untransfected HEK 293 cells (lanes 1 and 2), HEK 293 transfected with ADAMTS4.1-pCEP4 (lanes 3
and 4), or HEK 293 cells transfected with the ADAMTS4_v1-pCEP4 (lanes 5 and 6) and then probed with AltTS4.1 serum (D) or AltTS4.2 serum
(E).
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ure 2A). Identical Western blots of a detergent lysate
of ADAMTS-4_v1 were probed with affinity-purified
AltTS4.2 antibodies preincubated in the presence or ab-
sence of the immunizing peptide AltTS4.2. As expected,
the 104-kd band labeled with AltTS4.2, and this labeling
was abrogated by preincubation with the immunizing
peptide, thus confirming the specificity of this antibody.
To further confirm specificity, Western blots were per-
formed on ADAMTS-4 and ADAMTS-4_v1 purified by
anti-FLAG immunoprecipitation from detergent lysates
and conditioned media. Antibody AltTS4.1 detected a
104-kd band in ADAMTS-4_v1 purified from lysates
(Figure 2D), and staining was barely detectable in
ADAMTS-4_v1 purified from conditioned medium
(Figure 2D). In contrast, antibody AltTS4.2 reacted with
104- and 82-kd bands in ADAMTS-4_v1 purified from
conditioned medium (Figure 2E) and cell lysates (Figure
2E), and these appeared similar to bands detected on
duplicate Western blots probed with the anti–FLAG M2
mAb (Figure 1B). Additional bands were labeled by
AltTS4.2 in ADAMTS-4_v1 purified from cell lysates
(Figure 2E) and appeared similar to those seen in an
identical Western blot probed with the anti–FLAG M2
mAb (Figure 2B). No reactivity of either the AltTS4.1
or the AltTS4.2 antibody was seen with purified
ADAMTS-4 (Figures 2D and E) or with anti-FLAG
immunoprecipitates from untransfected HEK 293 cells
(Figures 2D and E).
In vivo protein expression of ADAMTS-4_v1.
In vivo protein expression of ADAMTS-4_v1 in synovial
tissue was investigated by Western blotting of short-
term cultures of OA synovial cells and immunohisto-
chemistry of OA synovial tissue (Figures 3A and C).
Western blotting with AltTS4.2 of cells isolated from
human OA synovium (Figure 3A) showed positive stain-
ing of a band migrating with a molecular weight of 70
kd. The specificity of this band was confirmed by peptide
inhibition (Figure 3A), where there was no staining for
this band after preincubation of AltTS4 with the immu-
nizing peptide.
Monolayers of untransfected or transfected
(ADAMTS4_v1-pCEP4 and ADAMTS4.1-pCEP4) HEK
293 cells were probed with the anti–FLAG M2 mAb or
with AltTS4.2 antibodies (Figure 3B). Untransfected
cells showed no staining. Strong staining of the trans-
fected cells was observed with the anti–FLAG M2 mAb.
No staining with AltTS4.2 was seen in cells transfected
with ADAMTS4.1-pCEP4, but strong staining was seen
on cells transfected with ADAMTS4_v1-pCEP4. Cryo-
sections of synovium from the knees of 2 patients with
OA were probed with AltTS4.2 and showed strong
staining in many areas of the synovial surface and villi
Figure 3. Analysis of synovial cells and synovium from patients with
osteoarthritis (OA) using the ADAMTS-4_v1 specific antibody AltTS4.2.
A, Western blots of a mixed cell population (coculture) isolated from OA
synovium. Purified recombinant ADAMTS-4_v1 and detergent lysates of
OA synovial cocultures were subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and Western blot analysis. Blots were
probed with affinity-purified AltTS4.2 that had been raised against a
synthetic peptide within the unique C-terminus of ADAMTS-4_v1 or
were probed with AltTS4.2 that had been preincubated with 5 g/ml of
the immunizing peptide. The asterisk indicates the band that stained with
the AltTS4.2 antibody in synovial cell lysates. B, Immunohistochemical
analysis of AltTS4.2 antibodies. Monolayers of untransfected HEK 293
cells or HEK 293 cells transfected with ADAMTS4.1-pCEP4 or
ADAMTS4_v1-pCEP4 were probed with affinity-purified AltTS4.2 anti-
bodies or the anti–FLAG M2 monoclonal antibody. Original magnifica-
tion 100. C, Immunohistochemical analysis of OA knee synovium using
AltTS4.2 antibodies. Cryosections of knee synovium from OA patient A
(1 and 2) and OA patient B (3 and 4) were incubated in the absence (1
and 3) or presence (2 and 4) of affinity-purified AltTS4.2. Sections were
counterstained with Mayer’s hemalum. Arrows indicate the synovial
membrane and villi surfaces. Bars  100 m.
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in both patients (Figure 3C). Staining was particularly
localized to the outer layer of cells in the villi of the
synovium. Underlying tissue was generally negative,
although occasional clusters of immunopositive cells
were observed. Tissue sections incubated without pri-
mary antibody (Figure 3C) showed no staining.
Proteolysis of ADAMTS-4_v1. Removal of the
pro domain by furin and/or autocatalysis of ADAMTS-4
results in activation of this enzyme (19). ADAMTS-4_v1
was incubated with furin for up to 3 hours at 37°C
and monitored for catalysis by Western blotting using
anti-FLAG and goat anti-human ADAMTS-4 anti-
bodies (R&D Systems) (Figure 4). Western blotting
showed decreased staining of the 104-kd band and a
corresponding increased staining of an 82-kd band,
showing that ADAMTS-4_v1 was cleaved by furin (Fig-
ure 4A). Furthermore, the intensity of staining of the
82-kd band at 3 hours appeared to be decreased in
comparison to staining intensity at 1 hour and 2 hours.
Western blotting with an antibody raised against the
whole ADAMTS-4 protein (Figure 4A) revealed multi-
ple catabolites of ADAMTS-4_v1 that increased over
the 3 hours. As these bands are not detected by the
C-terminal anti-FLAG, this suggests that the loss of the
82-kd band is most likely due to autocatalytic C-terminal
processing of ADAMTS-4_v1, as has been reported to
occur with ADAMTS-4 (20,21).
As autocatalysis has been reported for
ADAMTS-4 (19–21), we incubated ADAMTS-4_v1 at
37°C for up to 6 hours (Figure 4B). Western blotting
with antibody AltTS4.2 and anti-FLAG (data not
shown) showed a decrease in the intensity of staining of
the 104-kd band but no generation of an 82-kd band.
However, Western blotting with anti–ADAMTS-4
showed multiple catabolites that were not detected by
the C-terminal–domain antibodies. Furthermore, the
loss of the 104-kd band was inhibited in the presence of
5 mM EDTA (Figure 4C) and was not greatly inhib-
ited in the presence of tissue inhibitor of metallopro-
teinases 1 (TIMP-1; 24 nM) or TIMP-2 (23 nM). CaCl2
also modulated this C-terminal processing, as in its
absence, the enzyme remained as a 104-kd band (data
not shown). Collectively, these data indicate that the
loss of the 104-kd band is due to autolytic processing
either by the 104-kd protein or by an undetectable
amount of the 82-kd protein present in these prepara-
tions.
Enzyme substrate specificity of ADAMTS-4_v1.
To determine whether ADAMTS-4_v1 is capable of
cleaving aggrecan at the IGD cleavage site, we used a
commercially available aggrecanase 1 assay kit that in-
cluded a synthetic peptide aggrecanase 1 substrate. The
aggrecanase 1 activity of purified full-length ADAMTS-
4_v1 was compared to furin-activated ADAMTS-4_v1
and a truncated form of ADAMTS-4 (residues 213–579
of the full-length human ADAMTS-4). Preincubation
of ADAMTS-4_v1 showed the highest rate of increase
in relative fluorescence units (RFU), reaching satura-
tion after 10 minutes, and was 20–25-fold greater
than that of the full-length ADAMTS-4_v1 (Figure 5A).
Western blot analysis prior to assay showed the effi-
ciency of furin to generate the 82-kd form of the enzyme,
and postassay analysis demonstrated that the 82-kd form
was further processed during the 1-hour assay period
(Figures 5B and C).
To estimate the molar concentrations of active
Figure 4. Proteolysis of ADAMTS-4_v1. A, Western blots probed with anti–FLAG M2 monoclonal antibody (mAb) or affinity-purified polyclonal
goat antibodies to human ADAMTS-4 from purified ADAMTS-4_v1 that had been stored at 80°C during the course of the experiment (lane 0)
or had been incubated with 2 units of furin at 37°C for 1, 2, or 3 hours (lanes 1, 2, and 3, respectively). B, Western blots probed with affinity-purified
AltTS4.2, a rabbit antibody raised against a synthetic peptide representing a unique sequence in the C-terminus of ADAMTS-4_v1, or with
affinity-purified goat antibodies to human ADAMTS-4 from purified ADAMTS-4_v1 that had been stored at 80°C during the course of the
experiment (lane 0) or had been incubated at 37°C in the presence of 10 mM CaCl2 for 1, 3, or 6 hours (lanes 1, 3, and 6, respectively). C, Western
blot probed with anti–FLAG M2 mAb from purified ADAMTS-4_v1 that had been stored at 80°C during the course of the experiment (80°C)
or had been incubated for 6 hours at 37°C in the presence of 10 mM CaCl2 (control) or 10 mM CaCl2 plus 24 nM tissue inhibitor of
metalloproteinases 1 (TIMP-1), 23 nM TIMP-2, or 5 mM EDTA.
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ADAMTS-4_v1, densitometric analysis was performed.
The initial rate of digest of the recombinant trun-
cated form of ADAMTS-4 and active ADAMTS-4_v1
was calculated as 1,996 and 22,559 RFU/minute/pmole,
respectively, indicating that ADAMTS-4_v1 was 10
times more active than the truncated form. However,
this initial rate of reaction for ADAMTS-4_v1 is repre-
sentative of multiple C-terminally truncated forms. To
determine if ADAMTS-4_v1 could cleave native aggre-
can at the IGD site (EGE…ARG), aggrecan was incu-
bated with purified ADAMTS-4_v1 in the presence or
absence of furin to activate the enzyme during the
course of the experiment (Figure 6A). Cleavage at the
IGD site was detected by Western blotting using the
neoepitope mAb BC-3 (anti-ARG…). As shown in
Figure 6A, ADAMTS-4_v1 could generate the BC-3
epitope in the presence and absence of furin. The
increased activity generated by furin-activated versus
full-length ADAMTS-4_v1, as illustrated in Figure 5A,
was not observed when aggrecan was used as the sub-
strate, possibly due to differences in the experimental
conditions. In this experiment, the enzyme was not
Figure 5. Aggrecanase substrate activity of ADAMTS-4_v1, as assessed by SensoLyte 520 aggrecanase 1 assay. A, Aggrecanase 1 activity of an
anti–FLAG M2 immunoprecipitate from ADAMTS-4_v1 transfected with HEK 293 cells that had been predigested for 1 hour at 37°C with furin
(■) or an equal amount of undigested ADAMTS-4_v1 immunoprecipitate (), as compared to that of the recombinant truncated ADAMTS-4 (F)
(supplied in the assay kit). Enzyme activity (expressed as relative fluorescence units [RFU]) was measured every 5 minutes for 1 hour. B, Western
blot probed with anti–FLAG M2 monoclonal antibody from anti–FLAG M2 immunoprecipitates from ADAMTS-4_v1–transfected HEK 293 cells
used in A. Shown are undigested and furin-digested ADAMTS-4_v1 prior to their use in the assay (preassay) as well as undigested and furin-digested
ADAMTS-4_v1 plus recombinant truncated ADAMTS-4 (rADAMTS-4) that was harvested from the assay plate after the 1-hour course of the
aggrecanase 1 assay (postassay). C, Duplicate Western blot of B probed with affinity-purified goat anti-human ADAMTS-4 antibodies (BAF4307).
Figure 6. Enzyme activity of ADAMTS-4_v1 against proteoglycan substrates. A, Western blot of bovine aggrecan digested with anti-FLAG
immunoprecipitates from Triton X-100 extracts of untransfected HEK 293 cells (lanes 1 and 2), purified ADAMTS-4.1 (lanes 3 and 4), and
ADAMTS-4_v1 (lanes 5 and 6), in the absence (lanes 1, 3, and 5) or presence (lanes 2, 4, and 6) of furin. The blot was probed with neoepitope
monoclonal antibody (mAb) BC-3 to detect cleavage at the interglobular domain aggrecanase cleavage site. B, Western blot of aggrecan (lanes 4
and 8) and aggrecan that had been deglycosylated with chondroitinase ABC (lanes 1 and 5), chondroitinase ABC plus keratanase I and keratanase
II (lanes 2 and 6), or keratanase I plus keratanase II (lanes 3 and 7) digested with either ADAMTS-4.1 (lanes 1–4) or ADAMTS-4_v1 (lanes 5–8).
Cleavage at the interglobular domain aggrecanase site was detected with BC-3. C and D, Western blots of an A3 extract of cartilage digested with
anti-FLAG immunoprecipitates from Triton X-100 extracts of untransfected HEK 293 cells (lane 1), purified ADAMTS-4.1 (lane 2), or
ADAMTS-4_v1 (lane 3) and then probed with mAb PR-1, which is specific for biglycan (C), or mAb 70.6, which is specific for decorin (D).
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preactivated with furin, and an overnight digestion al-
lowed ample time for autoactivation of the enzyme in
the absence of furin. Detection of BC-3–positive bands
ranging from 200 kd to 37 kd indicated cleavage at
C-terminal sites by both enzymes (Figure 6A). After
overnight incubation, the amount of BC-3 epitope gen-
erated and the fragment pattern obtained by ADAMTS-
4_v1 appears to be equivalent to that generated by
ADAMTS-4 (Figure 6A, with or without furin).
To determine whether the glycosaminoglycan re-
quirements of ADAMTS-4_v1 digestion of aggrecan are
the same as those reported for ADAMTS-4 (22), native
aggrecan or aggrecan that had been predigested with
chondroitinase ABC, with chondroitinase ABC, kerata-
nase, and keratanase II, or with keratanase and kerata-
nase II was digested with either purified ADAMTS-4
or ADAMTS-4_v1 and subjected to Western blotting
using monoclonal antibody BC-3 (Figure 6B). Removal
of chondroitin sulfate or keratan sulfate glycosamino-
glycans greatly reduced the cleavage of aggrecan at
the IGD site by both ADAMTS-4 and ADAMTS-4_v1
(Figure 6B). With both enzymes, it appears that removal
of the keratan sulfate chains had a greater effect on
aggrecan cleavage at the IGD site than did removal of
the chondroitin sulfate chains (Figure 6B). These results
suggest that the presence of keratan sulfate glycosami-
noglycans facilitates IGD cleavage in aggrecan.
It has been reported that ADAMTS-4 is able
to cleave other proteoglycans (23–26). We thus tested
whether ADAMTS-4_v1 is capable of cleaving cartilage
biglycan and decorin using the A3 fraction from bovine
articular cartilage extracts as an enriched source of
biglycan and decorin. Digestions of the A3 fraction were
carried out with purified ADAMTS-4_v1 or ADAMTS-4.
A digest of aggrecan was carried out to confirm en-
zyme activity (data not shown). The biglycan-specific
antibody PR-1 labeled intact biglycan (37 kd) in A3
extracts that had been incubated with immunoprecipi-
tates from untransfected HEK 293 cells (Figure 6C). A
weak but noticeable reduction of biglycan labeling was
seen in the A3 extracts digested with either ADAMTS-4
or ADAMTS-4_v1 (Figure 6C), although no lower mo-
lecular weight proteolytic fragments could be detected
with this mAb. Antibody 70.6 labeled intact decorin in
the A3 extracts incubated with immunoprecipitates
from untransfected HEK 293 cells, and there was no
apparent difference in the labeling seen when A3 was
digested with purified ADAMTS-4_v1 or ADAMTS-4
(Figure 6D). No discernible proteolytic fragments could
be detected with this mAb in any of the digests.
DISCUSSION
We have previously shown (12) that OA synovial
cells produce an mRNA that codes for a splice variant of
ADAMTS4 (ADAMTS4_v1), producing a protein nearly
identical to ADAMTS-4 in which the spacer domain is
replaced with a nonhomologous C-terminal domain.
Herein, we have clearly shown that the splice variant
ADAMTS4_v1 is translated as a protein in human OA
synovium and synovial cells and that a purified recom-
binant ADAMTS-4_v1 is capable of cleaving aggrecan at
the pathological IGD aggrecanase site.
Previous studies have shown that recombinant
ADAMTS-4 is produced as a full-length protein in a
number of cell lines and is furin-activated, resulting
in removal of the pro domain prior to secretion as
lower molecular weight forms (19,21,26). The major
protein purified from ADAMTS-4_v1 cell lysates was
the pro domain 104-kd protein, along with small
amounts of the N-terminally processed (presumed to
be furin-activated) 82-kd protein. Similar pro domain
(95-kd) and furin-activated (70-kd) products were puri-
fied from ADAMTS-4 cell lysates. However, the only
furin-activated (70-kd) form of ADAMTS-4 was de-
tected in conditioned media, but surprisingly, the zymo-
gen form of ADAMTS-4_v1 was the predominant spe-
cies in the media from cell transfected with this plasmid.
The presence of the pro domain form in the media may
be due to cell death, or in contrast to ADAMTS-4, it
may be that ADAMTS-4_v1 is secreted from HEK 293
cells into the media mainly as the pro domain form.
Analysis of high salt extracts and plasma membrane
preparations strongly indicate that the variant is secreted
as a zymogen that associates with the cell membrane;
however, whether this is the case in vivo is still to be
determined. As reported for ADAMTS-4 (19), we found
that ADAMTS-4_v1 is cleaved by the proprotein con-
vertase furin. We have shown that ADAMTS-4_v1 is
susceptible to autocatalysis, which is inhibited by EDTA,
but not by TIMP-1 or TIMP-2. It seems likely that the
ADAMTS-4_v1 secreted with the pro domain attached
can be activated by extracellular pro domain convertase
(27,28), by self-activation, or by some other unknown
mechanism.
The sites of C-terminal cleavage for ADAMTS-
4_v1 may be similar to those reported in the literature,
where C-terminal processing of ADAMTS-4 involves
cleavage in the spacer domain at Lys694–Phe695 to pro-
duce a 53-kd form and at Thr581–Phe582 in the cysteine-
rich domain to produce a 40-kd form of ADAMTS-4, by
the action of membrane type 4 matrix metalloproteinase
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(at the cell membrane) or by autolysis (20,29). The
Thr581–Phe582 cleavage site is present on ADAMTS-
4_v1, and although the Lys694–Phe695 bond is conserved
in ADAMTS-4_v1, the sequence following the Arg696
diverges from that of ADAMTS-4, and this cleavage
site therefore may not be efficiently recognized. In
our studies using furin digestion of ADAMTS-4_v1
(Figures 4A and 5C), we observed extensive C-terminal
processing. In summary, it can be speculated that the C-
terminal domain may play a role in the overall stability,
processing, and substrate specificity of ADAMTS-4_v1.
Our work clearly showed that ADAMTS-4_v1
could cleave aggrecan at the IGD site in the aggrecan
core protein and other C-terminal sites, confirming
that the spacer domain does not play a crucial role in
cleavage at these sites. We also investigated the poten-
tial catabolism of decorin and biglycan. In those studies,
we observed loss of immunolabeling of biglycan di-
gested with either ADAMTS-4 or ADAMTS-4_v1, sug-
gesting that there was some catalytic activity against
this small leucine-rich proteoglycan. However, no di-
gestion of decorin was observed with either enzyme,
and this finding is in contrast to other published work
on ADAMTS-4 specificity (26). Our source of decorin
was a partially purified preparation, and so, perhaps
there were other more favorable substrates within this
preparation.
Antibodies to the C-terminal domain of ADAMTS-
4_v1 showed positive staining in OA synovium, confirm-
ing our mRNA data from synovial cell cocultures and
the translation of this message into protein in vivo.
The staining was most prominent in the superficial
layer of the synovial membrane, which are areas asso-
ciated with inflammation (30). In addition, we showed
that isolated OA synovial cells produced a 70–75 kd
ADAMTS-4_v1 protein. Taken together, these data
suggest that ADAMTS-4_v1 is produced in vivo and may
play a prominent role in the pathologic changes in OA
cartilage.
In conclusion, we have shown that the previously
described ADAMTS4_v1 mRNA (12) is translated into a
protein and that the recombinant protein is capable of
digesting both aggrecan and biglycan, but not decorin.
Importantly, we have localized this splice variant within
the OA synovial membrane, and we speculate that this
splice variant may play a role in aggrecan catabolism in
the superficial zone of articular cartilage with the onset
of OA.
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